title: Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
abstract: Analysis of HER-2/neu gene amplification by fluorescence in situ hybridization was performed in 40 patients with invasive bladder cancer in order to evaluate the potential for molecular targeted therapy of HER-2 as a tailor-made treatment for patients with invasive bladder cancer. This study included 40 patients seen at the Aichi Medical University Hospital from January 2001 to December 2004 and were pathologically diagnosed with invasive transitional cell carcinoma of the bladder (pT2-pT4). The PathVysion kit was used to evaluate the status of HER-2/neu gene amplification, and a signal ratio > or =2.0 was considered positive for HER-2/neu gene amplification. In primary foci 5 patients (12.5%) were positive for HER-2/neu gene amplification. According to the classification of grade and stage, no statistically significant difference was observed. Lymph node metastasis was found in 10 patients, and 3 patients (30%) were positive for HER-2/neu gene amplification. In the patients with HER-2/neu gene-amplified metastatic lymph nodes, primary foci were also positive for gene amplification, showing a statistically significant difference. This study indicates that 12.5% of patients with invasive bladder cancer may benefit from molecular targeted therapy of HER-2, and that molecular targeted therapy can be expected to be effective even for patients with lymph node metastases as long as their primary foci are positive for HER-2/neu gene amplification.
authors.affiliation: Department of Urology, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan. 101959@gk.amu.aichi-med-u.ac.jp
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Yamada
authors.forename: Katsuya
authors.initials: K
authors.lastname: Naruse
authors.forename: Kogenta
authors.initials: K
authors.lastname: Nakamura
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Aoki
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Taki
authors.forename: Motoi
authors.initials: M
authors.lastname: Tobiume
authors.forename: Kenji
authors.initials: K
authors.lastname: Zennami
authors.forename: Remi
authors.initials: R
authors.lastname: Katsuda
authors.forename: Miki
authors.initials: M
authors.lastname: Hirano
authors.forename: Keiko
authors.initials: K
authors.lastname: Hayashida
authors.forename: Emi
authors.initials: E
authors.lastname: Mizumukai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nanaura
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Honda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics*; D002295:Carcinoma, Transitional Cell / Q000235:genetics* / Q000556:secondary / Q000601:surgery; D005260:Female; D005784:Gene Amplification; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases